203 related articles for article (PubMed ID: 26636405)
1. Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
Sáez-Royuela F; Linares P; Cervera LA; Almohalla C; Jorquera F; Lorenzo S; García I; Karpman G; Badia E; Vallecillo MA; Moncada A; Calvo S; Olcoz JL;
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):305-12. PubMed ID: 26636405
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
5. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
6. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
[TBL] [Abstract][Full Text] [Related]
7. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
8. Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response.
Tachi Y; Hirai T; Kojima Y; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
Liver Int; 2018 Jan; 38(1):59-67. PubMed ID: 28557143
[TBL] [Abstract][Full Text] [Related]
9. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
Maasoumy B; Hunyady B; Calvaruso V; Makara M; Vermehren J; Haragh A; Susser S; Bremer B; Cloherty G; Manns MP; Craxì A; Wedemeyer H; Sarrazin C
PLoS One; 2014; 9(11):e110857. PubMed ID: 25389779
[TBL] [Abstract][Full Text] [Related]
10. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
11. Liver stiffness diminishes with antiviral response in chronic hepatitis C.
Hézode C; Castéra L; Roudot-Thoraval F; Bouvier-Alias M; Rosa I; Roulot D; Leroy V; Mallat A; Pawlotsky JM
Aliment Pharmacol Ther; 2011 Sep; 34(6):656-63. PubMed ID: 21752038
[TBL] [Abstract][Full Text] [Related]
12. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
13. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment.
Wu SD; Liu LL; Cheng JL; Liu Y; Cheng LS; Wang SQ; Ma W; Chen LP; Tseng YJ; Wang JY; Shen XZ; Jiang W
Clin Exp Med; 2018 Aug; 18(3):433-443. PubMed ID: 29696462
[TBL] [Abstract][Full Text] [Related]
15. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
[TBL] [Abstract][Full Text] [Related]
16. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study.
Facciorusso A; Del Prete V; Turco A; Buccino RV; Nacchiero MC; Muscatiello N
J Gastroenterol Hepatol; 2018 Apr; 33(4):942-949. PubMed ID: 28976021
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.
Wang JH; Changchien CS; Hung CH; Tung WC; Kee KM; Chen CH; Hu TH; Lee CM; Lu SN
J Gastroenterol Hepatol; 2010 May; 25(5):964-9. PubMed ID: 20546451
[TBL] [Abstract][Full Text] [Related]
18. Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
Lepida A; Colombo M; Fernandez I; Abdurakhmanov D; Ferreira PA; Strasser SI; Urbanek P; Mangia A; Calleja JL; Iraqi W; DeMasi R; Lonjon-Domanec I; Moreno C; Wedemeyer H
PLoS One; 2015; 10(9):e0138503. PubMed ID: 26398503
[TBL] [Abstract][Full Text] [Related]
19. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
[TBL] [Abstract][Full Text] [Related]
20. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
